ArticleAnnals of translational medicine2021
Long non-coding RNA ELFN1-AS1 in the pathogenesis of pancreatic cancer.
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- LncRNA ELFN1-AS1 maintains the stemness of colorectal cancer by preventing ubiquitinated degradation of the hnRNPA1 protein.Cellular and molecular life sciences : CMLS · 2026Article
- [High expression of ELFN1 is a prognostic biomarker and promotes proliferation and metastasis of colorectal cancer cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- The expression of the lncRNAs USP30-AS1, ELFN1-AS1, GAS8-AS1, and SNHG11 in breast cancer samples from Iranian patients from 2014 to 2019: a cross-sectional study.BMC research notes · 2025Article
- Construction of an immune-related prognostic model and potential drugs screening for esophageal cancer based on bioinformatics analyses and network pharmacology.Immunity, inflammation and disease · 2024Article
- Role of long non-coding RNA ELFN1-AS1 in carcinogenesis.Discover oncology · 2024Review
- The role of mitochondria-related lncRNAs in characterizing the immune landscape and supervising the prognosis of osteosarcoma.Journal of bone oncology · 2023Article
- Review
- lncRNA ELFN1-AS1 upregulates TRIM29 by suppressing miR-211-3p to promote gastric cancer progression.Acta biochimica et biophysica Sinica · 2023Article
- Epigenetic reprogramming in pancreatic premalignancy and clinical implications.Frontiers in oncology · 2023Review
- The Theory ofGenes · 2022Article
- Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma.Disease markers · 2022Article
- lncRNA ELFN1-AS1 enhances the progression of colon cancer by targeting miR-4270 to upregulate AURKB.Open medicine (Warsaw, Poland) · 2022Article
- The Role of Long Noncoding RNA AL161431.1 in the Development and Progression of Pancreatic Cancer.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong non-coding ribonucleic acid (lncRNA) ELFN1 antisense RNA 1 (ELFN1-AS1) is involved in the pathogenesis of many different cancers. But the current research on the relationship between lncRNA ELFN1-AS1 and pancreatic cancer is still blank.
methodsWe investigated the role of lncRNA ELFN1-AS1 in the pathogenesis of pancreatic cancer using bioinformatics,
resultsThrough bio-information analysis and
conclusionsThe experimental results show that the expression of LncRNA ELFN1-AS1 is related to the growth and invasion ability of pancreatic cancer cells. By further studying the function of LncRNA ELFN1-AS1 in pancreatic cancer, LncRNA ELFN1-AS1 was found to be involved in the epithelial-mesenchymal transition process in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.